2023
Sporadic pituitary adenoma with somatic double-hit loss of MEN1
Hong C, Alanya H, DiStasio M, Boulware S, Rimmer R, Omay S, Erson-Omay E. Sporadic pituitary adenoma with somatic double-hit loss of MEN1. Pituitary 2023, 26: 488-494. PMID: 37438451, DOI: 10.1007/s11102-023-01336-1.Peer-Reviewed Original ResearchPortable MRI to assess optic chiasm decompression after endoscopic endonasal resection of sellar and suprasellar lesions.
Hong C, Lamsam L, Yadlapalli V, Parasuram N, Mazurek M, Chavva I, Lalwani D, Zabinska J, Schiff S, Manes R, Vining E, Rimmer R, Kimberly W, Sheth K, Omay S. Portable MRI to assess optic chiasm decompression after endoscopic endonasal resection of sellar and suprasellar lesions. Journal Of Neurosurgery 2023, 139: 1664-1670. PMID: 37347618, DOI: 10.3171/2023.5.jns23174.Peer-Reviewed Original ResearchConceptsEndoscopic endonasal surgeryOptic nerve decompressionEndonasal surgerySuprasellar lesionsNerve decompressionOptic chiasmThird ventricleConventional MRIOptic chiasm compressionEndoscopic endonasal resectionChiasm compressionPreoperative imagingSingle institutionEndonasal resectionMRI availabilityRoutine MRISignificant interrater reliabilitySuprasellar pathologiesSurgeryNeurosurgical oncologyLinear mixed-effects modelsPortable MRIPatientsMRIMixed-effects modelsClinical and genomic differences in supratentorial versus infratentorial NF2 mutant meningiomas.
Tabor J, O'Brien J, Vasandani S, Vetsa S, Lei H, Jalal M, Marianayagam N, Jin L, Millares Chavez M, Haynes J, Dincer A, Yalcin K, Aguilera S, Omay S, Mishra-Gorur K, McGuone D, Morales-Valero S, Fulbright R, Gunel M, Erson-Omay E, Moliterno J. Clinical and genomic differences in supratentorial versus infratentorial NF2 mutant meningiomas. Journal Of Neurosurgery 2023, 139: 1648-1656. PMID: 37243548, DOI: 10.3171/2023.4.jns222929.Peer-Reviewed Original ResearchConceptsSubtotal resectionSupratentorial tumorsElevated Ki-67High-risk featuresProgression-free survivalChromosome 1p deletionInfratentorial counterpartsInfratentorial tumorsPostoperative managementSomatic driver mutationsCerebral convexityGrade IIInfratentorial meningiomasKi-67Posterior fossaLoss of heterozygosityMeningiomasResectionTumorsWhole-exome sequencing dataDriver mutationsHigh gradeSignificant differencesExome sequencing dataSporadic meningiomasFuture of Neurology & Technology: Neuroimaging Made Accessible Using Low-Field, Portable MRI
Parasuram N, Crawford A, Mazurek M, Chavva I, Beekman R, Gilmore E, Petersen N, Payabvash S, Sze G, Eugenio Iglesias J, Omay S, Matouk C, Longbrake E, de Havenon A, Schiff S, Rosen M, Kimberly W, Sheth K. Future of Neurology & Technology: Neuroimaging Made Accessible Using Low-Field, Portable MRI. Neurology 2023, 100: 1067-1071. PMID: 36720639, PMCID: PMC10259275, DOI: 10.1212/wnl.0000000000207074.Peer-Reviewed Original Research
2022
Pituitary Apoplexy
Hong C, Omay S. Pituitary Apoplexy. New England Journal Of Medicine 2022, 387: 2366-2366. PMID: 36547664, DOI: 10.1056/nejmicm2204942.Peer-Reviewed Original ResearchQuantitative epileptiform burden and electroencephalography background features predict post-traumatic epilepsy
Chen Y, Li S, Ge W, Jing J, Chen HY, Doherty D, Herman A, Kaleem S, Ding K, Osman G, Swisher CB, Smith C, Maciel CB, Alkhachroum A, Lee JW, Dhakar MB, Gilmore EJ, Sivaraju A, Hirsch LJ, Omay SB, Blumenfeld H, Sheth KN, Struck AF, Edlow BL, Westover MB, Kim JA. Quantitative epileptiform burden and electroencephalography background features predict post-traumatic epilepsy. Journal Of Neurology Neurosurgery & Psychiatry 2022, 94: 245-249. PMID: 36241423, PMCID: PMC9931627, DOI: 10.1136/jnnp-2022-329542.Peer-Reviewed Original ResearchConceptsPost-traumatic epilepsyTraumatic brain injuryCT abnormalitiesElectroencephalography featuresAdmission Glasgow Coma Scale scoreGlasgow Coma Scale scoreRetrospective case-control studyMultivariable logistic regression analysisRisk stratification modelCase-control studyLogistic regression analysisTBI admissionsSevere complicationsFuture trialsBrain injuryCT reportsSeizure diagnosisPredictive valueScale scorePatientsLogistic regressionStratification modelQuantitative electroencephalogramTBI mechanismsRegression analysisImpact of Frailty on Morbidity and Mortality in Adult Patients Undergoing Surgical Evacuation of Acute Traumatic Subdural Hematoma
Elsamadicy AA, Sandhu MRS, Freedman IG, Koo AB, Reeves BC, Yu J, Hengartner A, Havlik J, Hong CS, Rutherford HJV, Kim JA, Gerrard J, Gilmore EJ, Omay SB. Impact of Frailty on Morbidity and Mortality in Adult Patients Undergoing Surgical Evacuation of Acute Traumatic Subdural Hematoma. World Neurosurgery 2022, 162: e251-e263. PMID: 35276399, DOI: 10.1016/j.wneu.2022.02.122.Peer-Reviewed Original ResearchConceptsAcute traumatic subdural hematomaTraumatic subdural hematomaHospital mortalityNonroutine dischargeSubdural hematomaExtended LOSIndependent predictorsAdult patientsBaseline frailtyMultivariate logistic regression analysisExtended hospital lengthImpact of frailtyRetrospective cohort studyNational Trauma DatabaseLogistic regression analysisRegression analysisMultivariate regression analysisHealth care expendituresFrail patientsHospital lengthCohort studySurgical evacuationFrailty indexTrauma databasePatientsThe Role of Surgical Approaches in the Multi-Modal Management of Adult Craniopharyngiomas
Hong CS, Omay SB. The Role of Surgical Approaches in the Multi-Modal Management of Adult Craniopharyngiomas. Current Oncology 2022, 29: 1408-1421. PMID: 35323318, PMCID: PMC8947636, DOI: 10.3390/curroncol29030118.Peer-Reviewed Original ResearchConceptsSurgical approachBenign primary brain tumorsAggressive surgical resectionAdjuvant radiation therapyOptimal surgical approachInvasive surgical approachPrimary brain tumorsSurgical treatment paradigmMulti-modal managementEloquent neural structuresEndoscopic endonasal approachBenign biologyClinical sequelaeHypothalamic dysfunctionOpen resectionSurgical resectionSignificant morbidityOptic apparatusSafe resectionTumor recurrenceTranscranial surgeryTreatment paradigmDisease entityHypothalamic functionLateral approach
2021
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma
Lechner M, Takahashi Y, Turri-Zanoni M, Liu J, Counsell N, Hermsen M, Kaur RP, Zhao T, Ramanathan M, Schartinger VH, Emanuel O, Helman S, Varghese J, Dudas J, Riechelmann H, Sprung S, Haybaeck J, Howard D, Engel NW, Stewart S, Brooks L, Pickles JC, Jacques TS, Fenton TR, Williams L, Vaz FM, O'Flynn P, Stimpson P, Wang S, Hannan SA, Unadkat S, Hughes J, Dwivedi R, Forde CT, Randhawa P, Gane S, Joseph J, Andrews PJ, Royle G, Franchi A, Maragliano R, Battocchio S, Bewicke-Copley H, Pipinikas C, Webster A, Thirlwell C, Ho D, Teschendorff A, Zhu T, Steele CD, Pillay N, Vanhaesebroeck B, Mohyeldin A, Fernandez-Miranda J, Park KW, Le QT, West RB, Saade R, Manes RP, Omay SB, Vining EM, Judson BL, Yarbrough WG, Sansovini M, Silvia N, Grassi I, Bongiovanni A, Capper D, Schüller U, Thavaraj S, Sandison A, Surda P, Hopkins C, Ferrari M, Mattavelli D, Rampinelli V, Facchetti F, Nicolai P, Bossi P, Henriquez OA, Magliocca K, Solares CA, Wise SK, Llorente JL, Patel ZM, Nayak JV, Hwang PH, Lacy PD, Woods R, O'Neill JP, Jay A, Carnell D, Forster MD, Ishii M, London NR, Bell DM, Gallia GL, Castelnuovo P, Severi S, Lund VJ, Hanna EY. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. European Journal Of Cancer 2021, 162: 221-236. PMID: 34980502, PMCID: PMC9554673, DOI: 10.1016/j.ejca.2021.09.046.Peer-Reviewed Original ResearchConceptsPeptide radionuclide receptor therapyProphylactic neck irradiationDisease-free survivalOlfactory neuroblastomaSomatostatin receptor 2Stable diseaseAdjuvant radiotherapyNeck irradiationOverall survivalReceptor 2Potential efficacyPeptide receptor radionuclide therapyReceptor radionuclide therapyMultivariable survival analysisPertinent clinical dataClinical trial dataKey prognostic markersNodal recurrenceClinical outcomesClinicopathological characteristicsT stagePrognostic valueReceptor therapyDisease stageNeuroblastoma patientsSinonasal Glomangiopericytoma: Review of Imaging Appearance and Clinical Management Update for a Rare Sinonasal Neoplasm.
Al-Jobory YM, Pan Z, Manes RP, Omay SB, Ikuta I. Sinonasal Glomangiopericytoma: Review of Imaging Appearance and Clinical Management Update for a Rare Sinonasal Neoplasm. The Yale Journal Of Biology And Medicine 2021, 94: 593-597. PMID: 34970096, PMCID: PMC8686777.Peer-Reviewed Original ResearchConceptsWorld Health OrganizationParanasal sinusesNasal cavityClinical management updateRare sinonasal neoplasmSlight female predominanceLow malignant potentialComplete surgical excisionNon-specific appearanceCase of glomangiopericytomaDecade of ageAggressive treatmentExcellent prognosisSinus massFemale predominanceLocal excisionLocal recurrenceMale patientsSurgical excisionRare tumorMalignant potentialImaging appearancesSinonasal neoplasmsSinonasal cavityTumor extentComprehensive Genomic Characterization of A Case of Granular Cell Tumor of the Posterior Pituitary Gland: A Case Report
Hong CS, Elsamadicy AA, Fisayo A, Inzucchi SE, Gopal PP, Vining EM, Erson-Omay EZ, Omay S. Comprehensive Genomic Characterization of A Case of Granular Cell Tumor of the Posterior Pituitary Gland: A Case Report. Frontiers In Endocrinology 2021, 12: 762095. PMID: 34925233, PMCID: PMC8671743, DOI: 10.3389/fendo.2021.762095.Peer-Reviewed Original ResearchConceptsGranular cell tumorPosterior pituitary glandCell tumorsPituitary glandComprehensive genomic characterizationWhole-exome sequencingImmune checkpoint inhibitorsPoor clinical outcomePituitary gland tumorsHistone deacetylase inhibitorsInstitutional review boardRadiographic compressionUnderwent resectionCheckpoint inhibitorsMedical therapyPituitary massClinical outcomesOptic nerveSignificant morbidityResidual diseaseCase reportCentral hypothyroidismPharmacologic agentsGland tumorsTherapeutic targetingPIK3CA mutation in a case of CTNNB1 mutant sinonasal glomangiopericytoma
Hong C, Khan M, Sukys J, Prasad M, Erson-Omay EZ, Vining E, Omay SB. PIK3CA mutation in a case of CTNNB1 mutant sinonasal glomangiopericytoma. Molecular Case Studies 2021, 8: mcs.a006120. PMID: 34667073, PMCID: PMC8744496, DOI: 10.1101/mcs.a006120.Peer-Reviewed Original ResearchConceptsCase of glomangiopericytomaWhole-exome sequencingInstitutional review board-approved protocolTargeted medical therapyUnderwent surgical resectionPI3K/Akt/mTORWnt/β-cateninAkt/mTORPrimary sinonasal tumorSurgical resectionClinicopathologic characteristicsMedical therapyRare tumorPIK3CA mutationsSinonasal tumorsGlomangiopericytomaTumorsΒ-cateninSomatic mutationsComprehensive genetic characterizationGenomic characterizationMutationsConcurrent dysregulationResectionSinonasalType of bony involvement predicts genomic subgroup in sphenoid wing meningiomas
Jin L, Youngblood MW, Gupte TP, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera SM, Mishra-Gorur K, Blondin NA, Gorelick E, Omay SB, Pointdujour-Lim R, Judson BL, Alperovich M, Aboian MS, McGuone D, Gunel M, Erson-Omay Z, Fulbright RK, Moliterno J. Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomas. Journal Of Neuro-Oncology 2021, 154: 237-246. PMID: 34350560, DOI: 10.1007/s11060-021-03819-2.Peer-Reviewed Original ResearchConceptsSpheno-orbital meningiomasSphenoid wing meningiomaBony involvementTRAF7 mutationsGenomic subgroupsPre-operative clinical featuresTumor invasionYale-New Haven HospitalAdditional clinical variablesSubset of tumorsPre-operative predictionWhole-exome sequencingBone involvementBone invasionClinical featuresClinical variablesGrade IIMolecular subtypesRecurrence patternsClinical implicationsHyperostosisExome sequencingMeningiomasTumorsGenomic driversSomatic NF1 mutations in pituitary adenomas: Report of two cases
Hong CS, Kundishora AJ, Elsamadicy AA, Koo AB, McGuone D, Inzucchi SE, Omay SB, Erson-Omay EZ. Somatic NF1 mutations in pituitary adenomas: Report of two cases. Cancer Genetics 2021, 256: 26-30. PMID: 33862521, DOI: 10.1016/j.cancergen.2021.03.004.Peer-Reviewed Original Research
2020
Genetic characterization of an aggressive optic nerve pilocytic glioma
Hong CS, Fliney G, Fisayo A, An Y, Gopal PP, Omuro A, Pointdujour-Lim R, Erson-Omay EZ, Omay SB. Genetic characterization of an aggressive optic nerve pilocytic glioma. Brain Tumor Pathology 2020, 38: 59-63. PMID: 33098465, PMCID: PMC7585354, DOI: 10.1007/s10014-020-00383-x.Peer-Reviewed Original ResearchConceptsOptic nerve gliomaLeft optic nerve sheathLeft-sided visual lossSporadic adult casesOptic nerve sheathNeurofibromatosis type 1 syndromeType 1 syndromeWhole-exome sequencingEmpiric managementVisual lossFocal radiotherapyOptic nervePediatric populationNerve sheathOpen biopsyAdult casesBiopsy specimenBenign histopathologyClinical prognosticationPilocytic astrocytomaComplex tumorsActionable targetsVisual pathwayAdult populationTumor progressionAssociation of race and ethnicity to incident epilepsy, or epileptogenesis, after subdural hematoma.
Brown SC, King ZA, Kuohn L, Kamel H, Gilmore EJ, Frontera JA, Murthy S, Kim JA, Omay SB, Falcone GJ, Sheth KN. Association of race and ethnicity to incident epilepsy, or epileptogenesis, after subdural hematoma. Neurology 2020, 95: e2890-e2899. PMID: 32907969, PMCID: PMC7734738, DOI: 10.1212/wnl.0000000000010742.Peer-Reviewed Original ResearchConceptsSubdural hematomaEmergency departmentMultivariable Cox regressionRetrospective cohort studyMedical risk factorsDevelopment of epilepsyNontraumatic subdural hematomaAssociation of raceDiagnosis of epilepsyCohort studyPrimary outcomeRenal diseaseStatus epilepticusWhite patientsBlack patientsHospital revisitsCox regressionBlack raceDiagnosis codesRisk factorsClaims dataInjury severityEpilepsyDrug useSurvival analysisMolecular Diagnosis and Extracranial Extension in Cushing Disease
Hong CS, Murari K, Gossmann M, Mahajan A, Erson-Omay Z, Manes RP, Omay SB. Molecular Diagnosis and Extracranial Extension in Cushing Disease. JAMA Otolaryngology - Head & Neck Surgery 2020, 146: 865-867. PMID: 32644156, DOI: 10.1001/jamaoto.2020.1471.Peer-Reviewed Original ResearchDetecting Seizures and Epileptiform Abnormalities in Acute Brain Injury
Singla S, Garcia GE, Rovenolt GE, Soto AL, Gilmore EJ, Hirsch LJ, Blumenfeld H, Sheth KN, Omay SB, Struck AF, Westover MB, Kim JA. Detecting Seizures and Epileptiform Abnormalities in Acute Brain Injury. Current Neurology And Neuroscience Reports 2020, 20: 42. PMID: 32715371, PMCID: PMC9353690, DOI: 10.1007/s11910-020-01060-4.Peer-Reviewed Original ResearchConceptsIctal-interictal continuumBrain injuryAcute brain injuryBetter clinical outcomesTraumatic brain injuryRecent FindingsCurrent literatureIncreased morbidityClinical outcomesEpileptiform abnormalitiesEEG findingsMortality riskEEG monitoringEpileptiform patternsPrognostic modelSeizuresClinical settingInjuryLogistical barriersElectroencephalogram studyUse of EEGABIPractical barriersEEG analysisEEGMorbidityLarge-scale second-hit AIP deletion causing a pediatric growth hormone-secreting pituitary adenoma: Case report and review of literature
Gummadavelli A, Dinauer C, McGuone D, Vining EM, Erson-Omay EZ, Omay SB. Large-scale second-hit AIP deletion causing a pediatric growth hormone-secreting pituitary adenoma: Case report and review of literature. Journal Of Clinical Neuroscience 2020, 78: 420-422. PMID: 32336638, DOI: 10.1016/j.jocn.2020.04.103.Peer-Reviewed Original ResearchPembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet Oncology 2020, 21: 655-663. PMID: 32251621, PMCID: PMC7380514, DOI: 10.1016/s1470-2045(20)30111-x.Peer-Reviewed Original ResearchConceptsBrain metastasis responseYale Cancer CenterPD-L1 expressionPhase 2 trialUntreated brain metastasesBrain metastasesAdrenal insufficiencyAdverse eventsMetastasis responseCNS diseaseCancer CenterCohort 2Cohort 1Eastern Cooperative Oncology Group performance statusTreatment-related serious adverse eventsModified Response Evaluation CriteriaStage IV NSCLCTreatment-related deathsAcute kidney injuryPD-1 blockadeSerious adverse eventsSolid Tumors criteriaPhase 2 studyProportion of patientsResponse Evaluation Criteria